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The mainstay therapeutic strategy for metastatic castrate-resistant prostate cancer (CRPC) continues to be androgen deprivation
therapy usually in combination with chemotherapy or androgen receptor targeting therapy in either sequence, or recently approved
novel agents such as Radium223.However, immunotherapy has also emerged as an option for the treatment of this disease following
the approval of sipuleucel-T by the FDA in 2010. Immunotherapy is a rational approach for prostate cancer based on a body of
evidence suggesting these cancers are inherently immunogenic and,most importantly, that immunological interventions can induce
protective antitumour responses. Various forms of immunotherapy are currently being explored clinically, with the most common
being cancer vaccines (dendritic-cell, viral, and whole tumour cell-based) and immune checkpoint inhibition. This review will
discuss recent clinical developments of immune-based therapies for prostate cancer that have reached the phase III clinical trial
stage. A perspective of how immunotherapy could be best employed within current treatment regimes to achieve most clinical
benefits is also provided.
1. Introduction
Prostate cancer (PCa) is the most frequently diagnosed
cancer in men and the sixth leading cause of death from
cancer inmenworldwide [1]. An estimated 903,000menwere
newly diagnosed, and 258,000 died from PCa in 2008 [1].
When diagnosed at its early stages, PCa can be effectively
treated by surgery or radiation. However, up to one-third of
patientswith organ-confinedPCa eventually fail local therapy
and ultimately progress to advanced-staged or metastatic
disease within 10 years [2]. Approximately 4% of all newly
diagnosed patients present with metastatic disease, and up to
85% of patients diagnosed with CRPC have metastases [3].
2. Current Therapeutic Options for PCa
The normal prostate and PCa require androgens for growth
and optimal function of cell survival pathways [4]. After local
surgery or radiation, cancer control is monitored by Prostate
Specific Antigen (PSA), a prostate epithelial-specific protein
detected from secretions into the blood stream.The suppres-
sion of androgens by androgen deprivation therapy (ADT)
alone or together with androgen receptor (AR) antagonists
initially induces tumour regression and a period of cancer
control, accompanied by nondetectable or exceedingly low
PSA levels [5]. Ultimately, patients relapse, signalled by a
rise in PSA, and develop CRPC. Docetaxel (Taxotere) was
the first chemotherapy drug to show improved survival for
patients with CRPC, compared to the then standard of care,
mitoxantrone [6, 7]. More recently, cabazitaxel was FDA-
approved for patients who fail docetaxel therapy on the
basis of prolonged survival [8]. The seminal finding that
PCas can undertake de novo steroidogenesis and synthesis
of androgens and other steroids that reactivate the AR [9]
has underpinned the rationale for developing the steroid
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synthesis CYP17A1 inhibitor, abiraterone; this was approved
for clinical use after landmark trials showing extended sur-
vival after docetaxel failure [10, 11]. The new AR antagonist,
enzalutamide, is the latest drug to be FDA-approved inCRPC,
again on the basis of prolongation of survival compared
to placebo [12]. Cancer immunotherapy has recently been
introduced into the therapeutic landscape for CPRC fol-
lowing the approval of the dendritic-based cancer vaccine
sipuleucel-T (Provenge) by the FDA in 2010 [13]. The goal
of immunotherapy is to harness the powerful capabilities
of the immune system, comprising both the adaptive and
innate arms, to effectively recognise and kill transformed
cells whilst sparing healthy tissues. For excellent reviews on
the mechanisms of antitumour immunity induction, see [14–
16]. Currently, various forms of immunotherapy are being
investigated in clinical trials for PCa including dendritic cell-
based vaccines, immune checkpoint inhibition, viral-based
vector, and whole cell-based vaccines.
3. Immunotherapy Is Rational
for PCa Treatment
3.1. Androgen Deprivation and Immune Changes. Over the
past decade, strong evidence that PCa is inherently immuno-
genic has emerged, which underpins the rationale for using
immune-based therapies for this disease. PCa can stimulate
immune responses, as evidenced by induction of T cell
responses to cancers by various immunotherapies (see later
sections), and by histological data revealing the presence
of CD4+ T cells, CD8+ T cells, natural killer (NK) cells,
dendritic cells, andmacrophages within tumours. Early stud-
ies reported that prostate tumours with a dense infiltration
of lymphocytes correlated with longer patient survival and
that high grade prostatic adenocarcinomas have significantly
less infiltration of T cells and macrophages as compared
to benign nodular prostatic hyperplasia [25, 26], suggesting
that tumour progression could be associated with defects
in cell-mediated immune responses. Although subsequent
studies found that greater tumour infiltration of CD4+ T cells
can predict poorer prognosis [27], we now appreciate that
a proportion of these were likely regulatory T cells (Tregs),
which suppress immune responses through their inhibitory
actions at both the induction and effector phases. High
tumour infiltration of forkhead box P3- (foxp3-) expressing
cells (Tregs) was also found to correlate with higher baseline
PSA levels [28]. A high prevalence of regulatory T cells
within tumours is associated with more lethal PCa [29],
suggesting that therapeutic blockade of these cellsmay induce
beneficial clinical responses, by facilitating the generation
of effective cytotoxic immune responses. Increased NK cell
infiltrate within tumours was also found to be associated
with a lower risk of progression, providing evidence that
these innate immune cells may have a protective role against
PCa in humans [28]. A recent study reported that in organ-
confined PCa, the prevalent macrophage phenotype was M1
(tumour-inhibitory, promotes Th1 responses, proinflamma-
tory; defined as CD68+ by those authors) whereas in PCas
with extracapsular extension, M2 macrophages (tumour-
promoting, proangiogenic, promotes Th2 responses; defined
as CD163+) were more prevalent [30]. These findings,
together with another observation of reduced infiltration of
CD68+ macrophages associated with lymph node positivity
and higher clinical stage [31], indicate that reduced numbers
of macrophages with cytotoxic capabilities parallel more
aggressive disease; hence immune interventions that shift
the balance of macrophages to the M1 phenotype may
have antitumour effects. Despite this, it is important to
note that other studies have reported infiltration of CD68+
macrophages to correlate with poorer patient outcomes [28,
32]. While there is strong evidence that PCa is immunogenic,
it is also known that these cancers employ numerous immune
escape strategies that contribute to their growth and pro-
gression. Such escape mechanisms include defects in antigen
presentation (e.g., downregulation of HLA class I antigens
and beta-2 microglobulin to escape killing by cytotoxic T
cells), induction of T cell death (e.g., expression of Fas ligand
to trigger apoptosis of Fas-expressing immune cells), pro-
duction of immunosuppressive cytokines (e.g., transforming
growth factor-𝛽), and recruitment of regulatory T cells,
which limit immune responses [33]. These are challenges
that immunotherapies need to overcome, in order to deliver
clinical benefits to PCa patients.
Realistically, if immunotherapies are to be incorporated
into treatment regimens for PCa, they would most likely
be employed as adjunct therapies to ADT, the mainstay
approach for both high-risk early PCa and recurrent or
metastatic disease. Further evidence in support of the rational
use of immune-based therapies for PCa is that ADT seems to
enhance the influx of immune cells into tumours. Androgen-
depleted patients were reported to have a 5-fold increase
in CD4+ T cell infiltration, 2-fold increase in CD8+ T cell
infiltration, and 3-fold increase inmacrophages, as compared
to untreated tumours [34]. Moreover, hormone ablation
resulted in an increase in the number of tumour-resident cells
expressing the costimulatory molecules B7.1 and B7.2, which
are necessary for effective T cell activation [34]. A significant
proportion of T cells from patient tumours expressed IFN𝛾,
the proliferation marker Ki67, and exhibited a restricted
pattern of T cell receptor (TCR) beta-chain variable region
(V𝛽) gene usage, an oligoclonal response consistent with
an antigen-specific response [34]. Similar findings were
demonstrated in another report whereby androgen-depleted
tumours had a greater density of total T cells, as well as
the CD8+ T cell subset [28]. These results suggest that ADT
may augment antitumour immunity by enhancing T cell
activation as well as their trafficking to tumours. The relative
timing of androgen ablation with immunotherapy would be
crucial and warrants investigation.
3.2. TumourAssociatedAntigens andTheir Role in the Immune
Response. The existence of several tumour-associated anti-
gens (TAAs) provides further evidence in support of the
view that PCa would be amenable to immunotherapy; these
include the serine protease prostate specific antigen (PSA;
kallikrein 3), prostatic acid phosphatase (PAP), prostate spe-
cific membrane antigen (PSMA), prostate stem cell antigen
(PSCA), mucin-1 (MUC-1), and NY-ESO-1 [2]. Although
in a steady state these self antigens do not provoke strong
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immune responses, due to multiple layers of tolerance mech-
anisms, nevertheless, several immunotherapeutic strategies
have been shown to induce or enhance responses to these
antigens [2]. PSA, in addition to being selectively expressed
by prostate epithelial cells, is also a well-characterised serum
biomarker for PCa progression; therefore it also has utility in
the assessment of patient treatment response. Another char-
acteristic of PCa which renders it attractive for immunother-
apy is that it is a relatively slowly progressing disease, allowing
sufficient time for the immunologic intervention to take
effect. In addition, the prostate gland is nonessential for
life; therefore even if the immune response destroys normal
prostatic tissue, it would not be life-threatening or likely
to cause significant morbidity. Thus, immunotherapy is a
rational approach for PCa treatment.This review will discuss
recent clinical development of immune-based therapies for
PCa that have reached the phase III clinical trial stage, to
highlight the range of strategies currently being explored and
that show promise. These are sipuleucel-T (dendritic cell-
based vaccine), ipilimumab (immune checkpoint inhibitor),
Prostvac-VF (viral-based vaccine), and GVAX (whole cell-
based vaccine) (Table 1).
4. Sipuleucel-T (Dendritic Cell-Based Vaccine)
The rationale for using autologous dendritic cells in can-
cer immunotherapies is based on their efficient activation
of antigen-specific cytotoxic T cells to kill cancer cells.
Sipuleucel-T is a dendritic-based immunotherapy in which
autologous peripheral blood mononuclear cells (PBMCs)
are incubated ex vivo for 36–48 hours with a fusion pro-
tein (PA2024) of PAP and granulocyte-macrophage colony-
stimulating factor (GM-CSF) [35]. An analysis of culture
supernatant during the manufacture process showed an
increase in antigen presenting cell (APC) activation cytokines
(interleukin (IL)-1a, IL-23, macrophage inflammatory pro-
tein (MIP)-1a and -1b), T cell activation markers (IL-2,
-3, -4, -5, -10, and -17) as well as APC/T cell activation-
associated cytokines (IL-12, IFN𝛾, tumour necrosis factor
(TNF)) [36]. After sipuleucel-T treatment of autologous cells,
the product containing increased activated APCs and T cells
is reinfused into the patient and contains at least 50 million
autologous activated CD54+ dendritic cells, and a variable
number of T cells, B cells, natural killer cells, and others
[37]. Sipuleucel-T immunotherapy targets cells which express
PAP, a secreted glycoprotein enzyme that is expressed in
95% of prostate tissue and PCa; expression levels correlate
with tumour staging [38, 39]. Moreover, high serum PAP
levels are associated with significantly shorter survival and
lower responsiveness to radiation therapy [40].The GM-CSF
component of the fusion protein is an immune modulatory
cytokine that stimulates the development and maturation
of APCs, including type 1 dendritic cells (DC1), the subset
responsible for initiation of cytotoxic immune responses [41].
A key preclinical study which laid the groundwork for the
clinical development of sipuleucel-T demonstrated that mice
immunised with APCs incubated with a fusion protein of
rat PAP and rat GM-CSF developed profound prostatitis
(marked lymphocyte infiltrate), indicating that this approach
could break tolerance to the self-antigen [42, 43]. In a follow-
up experiment, coculture of PAP-expressing tumour cells
with splenocytes from animals immunised with APCs pulsed
with PAP and GM-CSF inhibited tumour cell proliferation
[42], showing the potential antitumour effect of the cancer
vaccine.These preclinical studies formed the basis for clinical
trials of sipuleucel-T.
In a sequential phase I/II clinical trial involving 31 men
with progressive disease despite ADT (12 with metastatic
disease in the phase I cohort and 19 with nonmetastatic
disease in phase II), sipuleucel-T was found to be well-
tolerated, with preliminary evidence of clinical efficacy [44].
100% patients developed T cell proliferative responses to
the fusion protein, PA2024, and 38% against native PAP,
following sipuleucel-T administration (none had preexisting
responses to either antigen), suggesting that immunological
tolerance against PA2024 and PAP could be broken by
this therapy [44]. Importantly, patients that developed an
immune response against PAP, whether in T cell proliferation
or antibody development, had significantly longer median
time to disease progression as compared to those who did
not (34 versus 13 weeks, resp.; 𝑃 < 0.027) [44]. In total, 6
patients had PSA value declines of greater than 25% from
baseline. In another phase I clinical trial of 13 patients with
similar clinicopathological characteristics, sipuleucel-T was
again well-tolerated, and all patients developed measurable
antigen-specific T cell responses and antibodies against
PA2024 after immunisation [45].
These promising findings led to the commencement of
three phase III clinical trials, all of which have now been
completed. In the first study (D9901), 127 patients with
asymptomatic metastatic CRPC were assigned in a 2 : 1 ratio
of sipuleucel-T (𝑛 = 82) or placebo (infusion of APCs not
pulsed with PA2024; 𝑛 = 45) [17]. While there was no differ-
ence in the primary endpoint of time to progression (TTP)
between the 2 treatment groups (11.7 weeks for sipuleucel-T
and 10.0 weeks for placebo), there was a significant increase
in the secondary endpoint of overall median survival for
those given sipuleucel-T (25.9 months versus 21.4 months)
[17]. Moreover, the survival rate at 36 months was signifi-
cantly higher (𝑃 = 0.005) for sipuleucel-T treated patients
(34%) when compared to placebo (11%). The clinical efficacy
of this dendritic-based immunotherapy was confirmed in
another similarly designed clinical trial of 98 patients (65 for
sipuleucel-T and 33 for placebo) (D9902A) [18]. No difference
in TTP was observed between the two groups, although the
median survival time was greater for sipuleucel-T-treated
patients over placebo (19.0 months versus 15.7 months, resp.),
consistent with the prior clinical trial [18]. The 36-month
survival rates were 33% (sipuleucel-T) and 15%, (controls).
A third phase III clinical trial known as the Immunotherapy
for Prostate Adenocarcinoma Treatment (IMPACT) trial was
undertaken; 512 patients were involved (341 on sipuleucel-
T and 171 on placebo) [19]. Consistent with previous trials,
sipuleucel-T treatment provided a 4.1 month improvement in
median survival (25.8 months versus 21.7 months), and the
36-month survival rate was 31.7% versus 23.0% [19].The time
to disease progression was similar between the treatment
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groups. Interestingly, multivariate analysis showed that base-
line PSA levels provided a strong prognostic factor, whereby
the overall survival hazard ratio in the lowest baseline PSA
quartile (<22.1 ng/mL) was 0.51 (0.31–0.85) compared with
the highest PSA quartile (<134 ng/mL) of 0.84 (0.55–1.29)
[46]. This finding suggests that patients with lower tumour
burden are more likely to benefit most from sipuleucel-
T and provides a rationale to employ this immunotherapy
as an early treatment strategy. Since the 3 aforementioned
phase III clinical trials were similarly designed, and recruited
patients with similar characteristics, an analysis for immune
parameters with overall survival was performed on pooled
data (𝑛 = 737) [36]. Overall survival significantly correlated
with development of at least one postbaseline peripheral
immune response (T cell proliferation, IFN𝛾 ELISPOT, or
antibody production) to PA2024 or PAP (HR = 0.47) (95%
CI: 0.29–0.78) [36]. In sipuleucel-T treated patients, a positive
correlation between overall survival and cumulative APC
activation (increase in CD54 expression on APCs; from pre-
to postculture with the fusion protein), APC count and
total nuclear cell (TNC) count were observed [36]. Whilst
these studies have collectively confirmed the clinical utility
of sipuleucel-T for the treatment of advanced PCa, some
questions remain as to why progression-free survival is unaf-
fected. One possible explanation relates to how progression is
defined, which in these studies is an increase in measurable
disease based on radiographic imaging, new cancer-related
pain associated with radiographic correlation, or other clin-
ical events consistent with progression such as spinal cord
compression or pathological fracture. The development of
new lesions could have been interpreted as progression yet
the diseasewas responding to treatment. Another speculation
is that the treatment gradually slows downprogression,which
is reflected in prolongation of overall survival, but short-term
improvements are not apparent. In addition, since the mode
of action of Sipuleucel-T is to activate the immune system,
a delay in treatment effect is expected. It is also important
to note that PSA levels generally do not alter in response to
Sipuleucel-T, further highlighting the difficulty in assessing
the therapeutic response.
5. Ipilimumab (Immune
Checkpoint Inhibitor)
T cell responses are initiated through the interaction of
the T cell receptor (TCR) with antigen presented in major
histocompatibility complex (MHC) molecules on antigen
presenting cells (APCs). However, the quality andmagnitude
of the response are dependent on a fine balance of costim-
ulatory and coinhibitory signals delivered to the T cell; for
an excellent review on T cell costimulation see [47]. CD28
(a costimulatory receptor) and cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) (a coinhibitory receptor) are
homologues that compete for their ligands, CD80 (B7-1)
and CD86 (B7-2) expressed on APCs [47]. CTLA-4 is a key
negative regulator of T cell responses and is upregulated
following T cell stimulation to attenuate the response. It
therefore functions as an immune checkpoint molecule.
CTLA-4 is also constitutively expressed on regulatory T cells
and mediates their immune suppressive effects [48]. From a
therapeutic point of view, CTLA-4 blockade could prevent
immune inactivation, leading to robust antitumour immune
responses. In a preclinical model of PCa, in vivo blockade of
murine CTLA-4 with an antibody significantly delayed the
growth of subcutaneous TRAMP-C1 tumours [49], derived
from Transgenic Adenocarcinoma of the Mouse Prostate
(TRAMP) mice [50, 51] which spontaneously develop PCas
due to prostate-specific expression of Simian virus 40 (SV40)
large T antigen (Tag). In a follow-up study, CTLA-4 blockade
prevented and/or slowed the outgrowth of subcutaneous
TRAMP-C2 tumours, which spontaneously metastasise to
the regional lymph nodes [52]. Moreover, anti-CTLA-4
antibody treatment after surgical resection of the primary
tumour facilitated the elimination of lymph node metastases,
suggesting that this immunotherapy has potential to be used
as an adjunct therapy to eliminate residual metastatic PCa
after surgery [52]. Based on these preclinical studies, clinical
trials of CTLA-4 blockade for PCa treatment have been
initiated.
Ipilimumab is a fully human IgG1 monoclonal antibody
that binds to and blocks the activity of CTLA-4. It was
approved by the FDA in 2011 for the treatment of advanced
melanoma on the basis of prolonged survival [53, 54].
Ipilimumab is currently being trialled for the treatment of
non-small cell lung cancer (NSCLC) [55], metastatic renal
cell cancer [56], ovarian cancer [57, 58], and PCa. In a
phase I clinical trial comprising 14 patients with progressive
metastatic CRPC (some of whom previously also received
chemotherapy or other investigational drugs), ipilimumab
treatment at 3mg/kg was well tolerated without the devel-
opment of significant pathological autoimmunity [59]. A
trend observed across the cohort was a gradual increase in
the percentage of CD4+ HLA DR+ T cells in peripheral
blood following ipilimumab treatment [59], consistent with
its mode of action in modulating immune activation. Two of
14 patients also had a >50% decline in PSA, which lasted for
135 and 60 days, respectively. In another phase I/II clinical
trial involving a similar cohort of PCa patients, ipilimumab
was administered alone or in combination with radiotherapy
(8Gy per bone target, up to 3 lesions per patient) [60]. The
maximal tolerable dose was determined as 10mg/kg, with
common immune-related adverse events such as diarrhoea,
colitis, and rash usually of grade 1/2 [60]. For patients that
received this dosage (with or without radiotherapy) (𝑛 =
50), eight had PSA declines of >50%, one had complete
response, and six had stable disease. These observations
indicated potential clinical antitumour activity of ipilimumab
and led to a phase III clinical trial that compared ipilimumab
against placebo after radiotherapy of mCRPC patients who
have failed docetaxel (𝑛 = 799) [20]. While there was no
significant difference in terms of overall survival (primary
endpoint) between the ipilimumab (11.2 months; 95% CI 5–
12.7) and placebo (10 months; CI 8.3–11) groups, there were
signs of activity with the drug [20]. Progression-free survival
at 6 months was 30.7% (95% CI 26–35.3) for ipilimumab, and
18.1% (14.3–22) for placebo. A decline in PSA levels (>50%
at any time) was also more frequent with the ipilimumab
6 BioMed Research International
group (13.1%; 9.5–17.5) than placebo group (5.2%; 3–8.4).
However, an exploratory and post-hoc subgroup analysis
showed overall survival benefit for ipilimumab after radio-
therapy in a subset of patients with favourable prognostic
features (no visceral metastases, nonraised or mildly raised
alkaline phosphatase, and without anaemia). The median
overall survival was 22.7 months for ipilimumab (𝑛 = 146),
as compared to 15.8 months for placebo (𝑛 = 142). This
apparent benefit from ipilimumab in patients with lower
tumour burden warrants further investigations, as it has
significant implications for further treatment studies using
ipilimumab for this disease.
6. Prostvac-VF (Viral-Based Vaccine)
Viral vectors are attractive for use in cancer immunotherapies
as they can mimic natural infection and lead to the induction
of robust immune responses against the tumour antigen(s)
that they encode [61]. Prostvac-VF (or PSA-TRICOM) is
a recombinant viral vaccine currently being trialled as an
immunotherapy for PCa that involves a prime and multiple
booster injections with attenuated strains of Vaccinia and
Fowlpox viruses, respectively [62]. Both recombinant viruses
are engineered to encode the entire PSA gene with amodified
agonist epitope (increases immunogenicity) and 3 costim-
ulatory proteins: B7-1 (facilitates T cell activation), lym-
phocyte function-associated antigen 3 (LFA-3; CD58), and
intercellular adhesion molecule-1 (ICAM-1; CD54) (both are
cell adhesion molecules that strengthen interactions between
APCs and T cells). The rationale behind this approach is that
the virus will directly infect the APCs (resulting in expression
of the costimulatory molecules), or somatic cells (epithelial
and/or fibroblasts) at the site of injection, leading to cell
death and subsequent uptake of cellular debris containing
PSA by the APCs [63]. The transduced APCs, or antigen-
loaded APCs, upon interaction with CD4+ and CD8+ T cells,
will effectively promote the development of T cell-mediated
immune responses that destroy PSA-expressing cancer cells.
The viral vectors are nonreplicative and do not integrate into
the genome of host cells, thus allowing for controlled admin-
istration of the transgenes [62]. Sequential injection of the
Fowlpox-based booster vaccine is designed to overcome the
reduced immunisation response following the development
of neutralising antibodies against theVaccinia-based priming
vaccine, so that a level of immunity is maintained. Several
preclinical studies have shown that the 3 costimulatory
molecules, commonly referred to as TRI-COM, act synergis-
tically to enhance antitumour immune responses to tumour
self-antigens [64]. For example, vaccination of transgenic
mice expressing human carcinoembryonic antigen (CEA-Tg)
with recombinant Vaccinia and Fowlpox vectors encoding
for CEA and TRI-COM can facilitate rejection of CEA-
expressing murine colon carcinomas, an effect dependent on
CD4+ and CD8+ T cells but not NK cells [64]. These mice
had a longer survival time and did not develop pathologic
autoimmunity based on biochemical, immunological, and
histological criteria, demonstrating the therapeutic potential
of this vaccine approach with minimal toxicity. Such studies
have formed the basis for the development of Prostvac-VF.
A number of phase I clinical trials have established the
safety and tolerability of Prostvac-VF [65, 66], and a phase
II study was used to optimise the sequence of vector admin-
istration (one Vaccinia prime followed by three Fowlpox
boosts) [67]. These findings led to the commencement
of a phase II randomised controlled trial of 125 patients
with minimally symptomatic CRPC (82 given Prostvac-
VF and 40 control empty viral vectors) [21]. Prostvac-VF
treatment was associated with longer overall survival time
(25.1 months) as compared with control (16.6 months)—
an improvement in median survival of 8.5 months [21].
The 3-year survival rate was almost double (30.5% versus
17.5%). However, no difference in progression-free survival
was observed between the 2 arms (primary endpoint). Con-
sistent with these findings, another phase II trial (nonran-
domised) reported that Prostvac-VF treatment correlated
with improved overall survival as compared with historical
controls (the Halabi nomogram) (26.6 versus 17.4 months);
the Halabi nomogram is a prognostic model developed on
historical data that is designed to predict survival of mCRPC
patients given docetaxel [22]. Importantly, patients with a
Halabi who predicted survival of <18 months had an actual
overall survival median of 14.6 months following Prostvac-
VF treatment, whereas for those with a Halabi prediction
of ≥18 months, it was ≥37.3 months (not yet reached) [22].
This suggests that patients with less aggressive or earlier-stage
disease are more likely to benefit most from this vaccine; this
could influence how Prostvac-VFmay be employed clinically.
Moreover, this study showed that 12 of 32 evaluable patients
(37.5%) showed a decline in serum PSA after vaccination,
and 2 of 12 patients with soft tissue metastases exhibited a
measurable decrease in index lesions by CT [22]. Recently,
an analysis of immunological impact by Prostvac-VF on
pooled data from several clinical trials conducted similarly
was published [68]. Collectively, 59 of 104 patients (57%) had
an increase in the number of PSA-specific T cells following
vaccination (median of 5-fold), and interestingly, 19 of 28
patients (68%) exhibited evidence of immune responses
mounted against other tumour-associated antigens not found
in the vaccine, for example, MUC1; a phenomenon known
as antigen spreading [68]. This could be another mechanism
thatmediates the antitumour effect of Prostvac-VF.Moreover,
the number and function of regulatory T cells were deceased
following vaccination, although no effect onNK cell numbers
was seen [68]. Due to these promising results, Prostvac-VF is
currently being investigated in phase III clinical trials.
7. GVAX (Whole-Cell Based Vaccine)
GVAX is a whole-cell vaccine comprised of a mixture
of 2 human PCa cell lines, LNCaP (androgen-sensitive;
derived from a lymph node metastasis) and PC3 (androgen-
insensitive; derived from a bone metastasis), which are
modified to constitutively express GM-CSF and irradiated
to prevent cell replication [69]. The rationale behind this
vaccine approach is to mount immune responses against
shared tumour antigens between the two allogeneic cell lines
and the host cancer, with GM-CSF enhancing this process
by functioning as a chemoattractant for dendritic cells as
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well as facilitating their maturation and antigen-presentation
to T cells to elicit robust antitumour effects [69]. The use
of allogeneic tumour cells as the core component also has
advantages in being faster and less expensive to manufacture
as compared to autologous tumour cells, which are tech-
nically more difficult to harvest. Several preclinical studies
have demonstrated that this whole-cell vaccine approach
can induce potent antitumour effects in a number of cancer
types. For example, subcutaneous injection of irradiated
murine B16 melanoma cells retrovirally modified to express
GM-CSF was associated with lower tumour take rate and
longer survival time as compared to nontransduced cells,
an antitumour effect mediated by both CD4+ and CD8+ T
cells [70]. In addition, mice injected with irradiated GM-
CSF-expressing tumour cells rejected a subsequent challenge
with nontransduced B16 cells, but not Lewis lung carcinoma
cells, indicating the vaccination induced strong protective
tumour-specific immune responses [70]. Similar results were
found in a preclinical model of PCa, whereby rats implanted
with irradiated MatLyLu prostate carcinoma cells engineered
to express GM-CSF exhibited longer disease-free survival
compared to those challenged with nontransduced cells
but also received soluble GM-CSF [71], indicating that the
continual tumour secretion of this cytokine facilitates the
development of antitumour immunity. These early studies
collectively formed the foundation for clinical trials of GVAX
for PCa.
A number of phase I/II clinical trials have demonstrated
the safety and tolerability of GVAX [72]. Early evidence for
clinical responses was observed in a phase II trial involving
55 men with chemotherapy-naive metastatic CRPC; 34 with
radiologic metastases (24 with high dose GVAX and 10 with
low dose); and 21 with rising PSA (all low dose) [73]. In the
radiologic group, the median time to PSA progression was
2.3 months for those given low dose, 3.7 months for high
dose, and for the PSA-rising group, it was 3.9 months [73].
The overall median survival time after treatment initiation
was 24 months (low dose) and 34.9 months (high dose) in
the radiologic group, whereas the estimated media survival
of these patients based on the Halabi nomogram was 19.5
months, showing a trend of increased survival time by GVAX
in a dose-dependent fashion. Moreover, there was evidence
for induction of antibodies to PC3 cell lysate (18/28; 64.3%)
andLNCaP (12/28; 64.3%) by patients in the radiologic group,
as shown by immunoblots with patient sera. In another
phase II clinical trial comprised of 80 men with the same
clinicopathological characteristics, treatment with high dose
was associated with longer median survival time (35 months)
as compared with those given medium dose (20 months)
and low dose therapy (23.1 months) [74]. The proportion
of patients that generated an antibody response to either
cell line was 89%, 72%, and 43%, respectively [74]. Collec-
tively, those who exhibited antibody induction had a median
survival of 34 months (n = 30), compared to 16 months
for those who did not (𝑛 = 6), suggesting that immune
reaction is associated with better clinical outcomes. These
promising results led to the two phase III clinical trials which
recruited men with metastatic CRPC comparing GVAX with
docetaxel-prednisone with (trial named VITAL-1) or without
(VITAL-2) cancer-related pain [75]. Unfortunately, VITAL-
2 (n = 408) was terminated early as preliminary analysis
demonstrated an excessive number of deaths (67 versus 47)
and shortermedian survival (12.2months versus 14.1months)
for GVAX and docetaxel patients, respectively [23]. Similarly,
VITAL-1 (n = 626) was also terminated early following a
futility analysis showing that GVAX was unlikely to meet its
primary endpoint of improved overall survival [24]. Despite
these disappointing phase III results of GVAX, this immune-
based agent is currently being trialled in combination with
other immunotherapies, for example, Ipilimumab for PCa
[76].
8. A Perspective on the Future of
Immunotherapy for PCa
Since ADT plays a central role in the treatment of high-risk
early PCa and recurrent or metastatic disease, it is crucial
that immune-based therapies are compatible and, preferably,
show synergistic activity. There is already preclinical and
clinical evidence suggesting that ADT augments antitu-
mour immunity through enhancement of T cell activation
and trafficking to tumours [28, 34, 77, 78]. In addition,
a reduction in tumour burden achieved through ADT (or
surgery, chemotherapy, or other agents)may increase tumour
sensitivity to immune-mediated destruction, as tumours can
be highly immunosuppressive [79]. Moreover, the immune
system is more likely to eliminate residual disease/low
tumour volume than bulky lesions, a concept supported by
the trend of longer survival time by sipuleucel-T or Prostvac-
VF in patients with lower tumour burden [22, 46]. Recently,
a phase II trial comprising nonmetastatic CRPC patients
reported that Prostvac-VF, used in combination with the AR
antagonist flutamide, was associatedwith longermedian time
to progression as compared to flutamide alone (233 days
versus 85 days, resp.) [80], highlighting the potential of this
combined approach. In terms of treatment sequencing, two
phase II clinical trials provided early evidence that adminis-
tration of ADT (nilutamide) after the immunological agent
is associated with longer median survival [81] and median
time to treatment failure [82], as compared to the reverse
sequence. A possible explanation is that the immune mod-
ulatory effects of ADT augmented the antitumour immune
responses initiated by Prostvac-VF. The optimal timing and
sequence of Sipuleucel-T with novel hormone therapies
such as abiraterone and enzalutamide are currently being
investigated in phase II and III clinical trials, with the results
being much anticipated [37, 83]. Similarly, the development
of PD1 and PDL1 immune checkpoint inhibitors has attracted
much interest [63]. Whilst occasional PCa patients have been
enrolled in the phase I trials of these compounds, there
has been no particular signal of activity in CRPC to date.
Nevertheless, learning to harness PD1 and PDL1 inhibitors
into the therapeutic armamentarium for CRPC would seem
to be a priority.
Combination immunotherapy is another rational strategy
to substantially enhance clinical outcomes by employing
different agents that work via varied mechanisms of action
and are potentially synergistic. A strategy that is receiving
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increasing attention is the combination of ipilimumab with
Prostvac-VF. The goal is to reduce or eliminate regulatory
elements during the induction and/or effector phases of anti-
tumour immunity (ipilimumab), to further boost responses
to the target antigen PSA (Prostvac-VF). A recent phase
I trial of ipilimumab/Prostvac-VF combination reported
encouraging results, with men treated with both agents
having an overall survival of approximately 34 months. This
compares favourablywith historical controls of previous trials
which used vaccine alone (26 months) [62, 84]. Moreover,
there was evidence for antigen cascade induction, that is,
immune responses developed against antigens not encoded
in the vaccine, and that the combination did not seem to
exacerbate the immune-related adverse events associated
with ipilimumab. There are also trials now investigating
the combination of GVAX with ipilimumab [76, 85]. While
GVAX as a monotherapy had limited efficacy in phase III
trials, it is an attractive candidate for combined usage with
ipilimumab as the latter may augment immune responses
to multiple tumour antigens. A recent phase I trial of ipili-
mumab and GVAX was well tolerated, and 25% of patients
exhibited decline in PSA levels [85].
Chemoimmunotherapy is also a potentially useful
approach for CRPC. In the past, chemotherapy was thought
to compromise immune responses by way of lymphocyte
lysis as a bystander effect of its mode of mechanism on
actively dividing cancer cells. However, there is growing
evidence that chemotherapy can induce immunemodulatory
effects that could facilitate the induction of antitumour
immunity. For example, docetaxel has been reported to
increase the production of proinflammatory cytokines
[86], cyclophosphamide to decrease Tregs [87], cisplatin to
upregulate the apoptosis ligand Fas [88], and doxorubicin
to enhance cytotoxic T cell antitumour immunity [89].
However, the feasibility of chemoimmunotherapy for PCa
remains to be determined, as early phase clinical trial results
have so far been inconclusive. A phase II clinical trial
involving men with metastatic CRPC reported that those
given Prostvac-VF concurrently with docetaxel had longer
progression-free survival than patients given the vaccine
alone (3.2 months versus 1.8 months) [90], but this clearly
needs to be validated in large prospective trials. On the other
hand, a phase III trial that investigated the effects of GVAX
plus docetaxel was terminated early following preliminary
findings that the combination treatment was associated with
shorter survival and had a higher death rate compared to the
docetaxel plus prednisone control group [91]. To properly
assess the clinical utility of chemoimmunotherapy, it is
necessary to consider the optimal timing and scheduling of
treatments.
9. Summary
While enzalutamide [12], abiratirone [10], and cabazitazel [8]
have been shown to be efficacious in the postdocetaxel setting
by prolonging survival, they are not curative; hence, novel
therapies need to be integrated into treatment regimes to
further improve patient outcome. Immunotherapy has the
potential to meet this need, following the demonstration
that some approaches can improve patient survival [19]
and that other immune therapies may synergise with ADT
[80] or with each other in their anticancer activity. The
realisation that PCa is inherently immunogenic and, more
importantly, can be targeted by the immune system through
immunemodulatory agents is driving intense research in this
field. Various approaches are being explored, although only
dendritic cell-based vaccines, immune checkpoint inhibition,
viral vector, and tumour-based vaccines have reached phase
III clinical trial endpoints to date. Key questions remain,
including the mode of achieving immune modulation (vac-
cine? immune suppression modulation? TAAs?), timing of
immune therapy according to stage of disease, sequence of
treatments, and which candidate treatments might best be
paired with immune therapy.
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